BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 32212232)

  • 1. Prostate cancer in Pennsylvania: The role of older age at diagnosis, aggressiveness, and environmental risk factors on treatment and mortality using data from the Pennsylvania Cancer Registry.
    Bluethmann SM; Wang M; Wasserman E; Chen C; Zaorsky NG; Hohl RJ; McDonald AC
    Cancer Med; 2020 May; 9(10):3623-3633. PubMed ID: 32212232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temporal and spatial trends and determinants of aggressive prostate cancer among Black and White men with prostate cancer.
    Wang M; Chi G; Bodovski Y; Holder SL; Lengerich EJ; Wasserman E; McDonald AC
    Cancer Causes Control; 2020 Jan; 31(1):63-71. PubMed ID: 31732913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors associated with initial treatment and survival for clinically localized prostate cancer: results from the CDC-NPCR Patterns of Care Study (PoC1).
    Schymura MJ; Kahn AR; German RR; Hsieh MC; Cress RD; Finch JL; Fulton JP; Shen T; Stuckart E
    BMC Cancer; 2010 Apr; 10():152. PubMed ID: 20403178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Racial and Ethnic Differences in Health Behaviors and Preventive Health Services Among Prostate Cancer Survivors in the United States.
    Li J; Thompson TD; Richards TB; Steele CB
    Prev Chronic Dis; 2016 Jul; 13():E95. PubMed ID: 27442995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer.
    Ham WS; Chalfin HJ; Feng Z; Trock BJ; Epstein JI; Cheung C; Humphreys E; Partin AW; Han M
    Eur Urol; 2017 Jun; 71(6):907-912. PubMed ID: 27876305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lifestyle behaviors, obesity, and perceived health among men with and without a diagnosis of prostate cancer: a population-based, cross-sectional study.
    Rogers LQ; Courneya KS; Paragi-Gururaja R; Markwell SJ; Imeokparia R
    BMC Public Health; 2008 Jan; 8():23. PubMed ID: 18211697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Racial Differences in Prostate Cancer Treatment: The Role of Socioeconomic Status.
    Watson M; Grande D; Radhakrishnan A; Mitra N; Ward KR; Pollack CE
    Ethn Dis; 2017; 27(3):201-208. PubMed ID: 28811730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
    Conde FA; Sarna L; Oka RK; Vredevoe DL; Rettig MB; Aronson WJ
    Urology; 2004 Aug; 64(2):335-40. PubMed ID: 15302490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of travel distance to the treatment facility on overall mortality in US patients with prostate cancer.
    Vetterlein MW; Löppenberg B; Karabon P; Dalela D; Jindal T; Sood A; Chun FK; Trinh QD; Menon M; Abdollah F
    Cancer; 2017 Sep; 123(17):3241-3252. PubMed ID: 28472547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Receipt of definitive therapy in elderly patients with unfavorable-risk prostate cancer.
    Yang DD; Mahal BA; Muralidhar V; Boldbaatar N; Labe SA; Nezolosky MD; Vastola ME; Beard CJ; Martin NE; Mouw KW; Orio PF; King MT; Nguyen PL
    Cancer; 2017 Dec; 123(24):4832-4840. PubMed ID: 28832984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spatial patterns in prostate Cancer-specific mortality in Pennsylvania using Pennsylvania Cancer registry data, 2004-2014.
    Wang M; Wasserman E; Geyer N; Carroll RM; Zhao S; Zhang L; Hohl R; Lengerich EJ; McDonald AC
    BMC Cancer; 2020 May; 20(1):394. PubMed ID: 32375682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Could Differences in Treatment Between Trial Arms Explain the Reduction in Prostate Cancer Mortality in the European Randomized Study of Screening for Prostate Cancer?
    Carlsson SV; MĂ„nsson M; Moss S; Kwiatkowski M; Recker F; Tammela TLJ; Bangma C; Roobol MJ; Auvinen A; Hugosson J
    Eur Urol; 2019 Jun; 75(6):1015-1022. PubMed ID: 30928162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer.
    Muralidhar V; Catalano PJ; Reznor G; Mahal BA; Choueiri TK; Sweeney CJ; Martin NE; Beard CJ; Chen YW; Nezolosky MD; Hoffman KE; Feng FY; Trinh QD; Nguyen PL
    J Natl Compr Canc Netw; 2016 Apr; 14(4):421-8. PubMed ID: 27059190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Causes of mortality after dose-escalated radiation therapy and androgen deprivation for high-risk prostate cancer.
    Tendulkar RD; Hunter GK; Reddy CA; Stephans KL; Ciezki JP; Abdel-Wahab M; Stephenson AJ; Klein EA; Mahadevan A; Kupelian PA
    Int J Radiat Oncol Biol Phys; 2013 Sep; 87(1):94-9. PubMed ID: 23920389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overall survival and prognostic factors prostate cancer in Kurdistan Province-Iran: a population-based study (2011-2018).
    Rasouli MA; Moradi G; Zareie B; Sofimajidpour H; Tozandehjani S; Zafari H; Gholami F; Shahsavari S; Hassani P; Mohammadian M
    BMC Cancer; 2021 Dec; 21(1):1314. PubMed ID: 34876069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential Risk of Castration Resistance After Initial Radical Prostatectomy or Radiotherapy for Prostate Cancer.
    Obata H; Shiota M; Akitake N; Takeuchi A; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Eto M
    Anticancer Res; 2017 Oct; 37(10):5631-5637. PubMed ID: 28982880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer.
    Kishan AU; Cook RR; Ciezki JP; Ross AE; Pomerantz MM; Nguyen PL; Shaikh T; Tran PT; Sandler KA; Stock RG; Merrick GS; Demanes DJ; Spratt DE; Abu-Isa EI; Wedde TB; Lilleby W; Krauss DJ; Shaw GK; Alam R; Reddy CA; Stephenson AJ; Klein EA; Song DY; Tosoian JJ; Hegde JV; Yoo SM; Fiano R; D'Amico AV; Nickols NG; Aronson WJ; Sadeghi A; Greco S; Deville C; McNutt T; DeWeese TL; Reiter RE; Said JW; Steinberg ML; Horwitz EM; Kupelian PA; King CR
    JAMA; 2018 Mar; 319(9):896-905. PubMed ID: 29509865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
    Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer.
    Westover K; Chen MH; Moul J; Robertson C; Polascik T; Dosoretz D; Katin M; Salenius S; D'Amico AV
    BJU Int; 2012 Oct; 110(8):1116-21. PubMed ID: 22540922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.